Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case–control study

BACKGROUND: The aromatase inhibitor (AI)-associated musculoskeletal syndrome (AIMSS) occurs in approximately 50% of AI-treated patients. Inflammatory mediators are associated with oestrogen signalling and may change with oestrogen depletion. We hypothesised that AIMSS may be associated with changes...

Descripción completa

Detalles Bibliográficos
Autores principales: Henry, N L, Pchejetski, D, A'Hern, R, Nguyen, A T, Charles, P, Waxman, J, Li, L, Storniolo, A M, Hayes, D F, Flockhart, D A, Stearns, V, Stebbing, J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2920022/
https://www.ncbi.nlm.nih.gov/pubmed/20606683
http://dx.doi.org/10.1038/sj.bjc.6605768

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2920022/
https://www.ncbi.nlm.nih.gov/pubmed/20606683
http://dx.doi.org/10.1038/sj.bjc.6605768

Ejemplares similares